AstraZeneca PLC's latest 6-K report reveals The Capital Group's increase in voting rights to 5.01%. Insights on shareholder dynamics and corporate governance implications included.
Explore AstraZeneca PLC's August 2025 Form 6-K report detailing The Capital Group's voting rights changes, impacting governance. Key insights on acquisitions and shareholder dynamics.
Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.
Explore AstraZeneca's Q2 2025 financial report, highlighting $28.045B revenue, 8% growth, and a strong investment recommendation.
This SEC Form 6-K reveals AstraZeneca's Phase III results for Gefurulimab in treating gMG, highlighting significant improvements in daily living activities and a solid safety profile.
AstraZeneca plans to invest $50B in US manufacturing and R&D by 2030, aiming for $80B revenue. This will create tens of thousands of jobs and enhance drug production capabilities.
Explore AstraZeneca's latest report on anselamimab's Phase III trial for AL amyloidosis, highlighting key findings and future steps.
AstraZeneca's Baxdrostat shows significant promise in treating uncontrolled hypertension, marking a major advancement in cardiovascular medicine.
AstraZeneca announces EU approval of Imfinzi for muscle-invasive bladder cancer, showing significant survival benefits and addressing critical treatment needs.
Discover AstraZeneca's total voting rights and regulatory compliance in the July 2025 report, vital for shareholders and investor relations.
AstraZeneca PLC announces the approval of Datroway for advanced EGFR-mutated lung cancer, highlighting clinical trial success and strategic collaboration with Daiichi Sankyo.
Explore AstraZeneca's strategic collaboration with CSPC Pharmaceuticals, focusing on AI-enabled drug discovery for chronic diseases, with potential milestones of over $5 billion.